Gilead Signs an Exclusive License Agreement with Jounce for Cancer Immunotherapies

Shots:

• Jounce to receive $85M up front, $685B as clinical, regulatory, and commercial milestone payments, $35M equity investment at a premium in Jounce upon closing along with royalties on global sales of therapies including JTX-1811. The transaction is expected to be closed in H2’20
• Jounce will lead the development of JTX-1811 through IND clearance, and thereafter, Gilead will be solely responsible to develop the therapy
• JTX-1811 is a mAb, targeting CCR8 and selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells

Click here ­to­ read full press release/ article | Ref: Gilead | Image: Dragon Images